Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Maze Therapeutics, Inc. (MAZE) had Tangible Shareholders Equity of $292.07M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-32.79M |
|
-- |
|
-- |
|
$35.40M |
|
$-35.40M |
|
$2.62M |
|
$-32.79M |
|
$-32.79M |
|
$-32.79M |
|
$-32.79M |
|
$-32.79M |
|
$-32.79M |
|
$-35.40M |
|
$-34.72M |
|
28.63M |
|
28.63M |
|
$-1.15 |
|
$-1.15 |
|
| Balance Sheet Financials | |
$299.71M |
|
$6.31M |
|
$33.13M |
|
$332.84M |
|
$18.62M |
|
-- |
|
$22.16M |
|
$40.77M |
|
$292.07M |
|
|
Tangible Shareholders Equity |
$292.07M |
$292.07M |
|
43.80M |
|
| Cash Flow Statement Financials | |
$-29.52M |
|
$-0.30M |
|
$127.38M |
|
$197.90M |
|
$295.46M |
|
$97.56M |
|
$3.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.23% |
|
-11.23% |
|
-9.85% |
|
-11.23% |
|
$6.67 |
|
$-1.04 |
|
$-1.03 |
|